BEHIND THE NEWS: Even after Zyprexa victory, Lilly faces many obstacles
On the surface, the news about Eli Lilly and Co. in recent days has been almost all good. The company averted catastrophe by prevailing in an Indianapolis lawsuit challenging U.S. patent protection for the blockbuster Zyprexa. Then it announced first-quarter profit that beat analysts’ consensus by two pennies a share. Pessimists who take a closer look, however, may want to pop a Prozac. Analysts note that the stable of new drugs that are supposed to pick up the slack as…